These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 24060147)

  • 1. Osteoporosis and its association with non-gonadal hormones involved in hypertension, adiposity and hyperglycaemia.
    Poudyal H; Brown L
    Curr Drug Targets; 2013 Dec; 14(14):1694-706. PubMed ID: 24060147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis.
    Tsentidis C; Gourgiotis D; Kossiva L; Doulgeraki A; Marmarinos A; Galli-Tsinopoulou A; Karavanaki K
    Osteoporos Int; 2016 Apr; 27(4):1631-1643. PubMed ID: 26588909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic Activation of Activin A Signaling Causes Chronic Kidney Disease-Mineral Bone Disorder.
    Sugatani T
    Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30142896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The many ways of osteoclast activation.
    Lorenzo J
    J Clin Invest; 2017 Jun; 127(7):2530-2532. PubMed ID: 28530641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells.
    Kondo H; Guo J; Bringhurst FR
    J Bone Miner Res; 2002 Sep; 17(9):1667-79. PubMed ID: 12211438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoprotective Effect of Cimiracemate in Glucocorticoid-Induced Osteoporosis by Osteoprotegerin/Receptor Activator of Nuclear Factor κ B/Receptor Activator of Nuclear Factor Kappa-Β Ligand Signaling.
    Ding Z; Shi H; Yang W
    Pharmacology; 2019; 103(3-4):163-172. PubMed ID: 30695776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The OPG/RANKL/RANK system and bone resorptive disease].
    Liu JZ; Ji ZL; Chen SM
    Sheng Wu Gong Cheng Xue Bao; 2003 Nov; 19(6):655-60. PubMed ID: 15971575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenesis of osteoporosis: concepts, conflicts, and prospects.
    Raisz LG
    J Clin Invest; 2005 Dec; 115(12):3318-25. PubMed ID: 16322775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone loss in the spondyloarthropathies: role of osteoclast, RANKL, RANK and OPG in the spondyloarthropathies.
    Anandarajah AP; Schwarz EM
    Adv Exp Med Biol; 2009; 649():85-99. PubMed ID: 19731622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis.
    Dougall WC
    Clin Cancer Res; 2012 Jan; 18(2):326-35. PubMed ID: 22031096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell-based assay strategy for identification of motif-specific RANK signaling pathway inhibitors.
    Chen T; Feng X
    Assay Drug Dev Technol; 2006 Aug; 4(4):473-82. PubMed ID: 16945019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Signaling axis in osteoclast biology and therapeutic targeting in the RANKL/RANK/OPG system.
    Tanaka S
    Am J Nephrol; 2007; 27(5):466-78. PubMed ID: 17652963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
    J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.
    Michael H; Härkönen PL; Väänänen HK; Hentunen TA
    J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Zuoguiwan on osteoporosis in ovariectomized rats through RANKL/OPG pathway mediated by β2AR.
    Liu F; Tan F; Tong W; Fan Q; Ye S; Lu S; Teng Z; Han M; Zhang M; Chai Y
    Biomed Pharmacother; 2018 Jul; 103():1052-1060. PubMed ID: 29710663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of receptor activator of nuclear factor-kappa B ligand and osteoprotegerin mRNA expression by parathyroid hormone is predominantly mediated by the protein kinase a pathway in murine bone marrow cultures.
    Lee SK; Lorenzo JA
    Bone; 2002 Jul; 31(1):252-9. PubMed ID: 12110442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting of the osteoclastogenic RANKL-RANK axis prevents osteoporotic bone loss and soft tissue calcification in coxsackievirus B3-infected mice.
    Lee K; Kim H; Park HS; Kim KJ; Song H; Shin HI; Kim HS; Seo D; Kook H; Ko JH; Jeong D
    J Immunol; 2013 Feb; 190(4):1623-30. PubMed ID: 23303667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review).
    Liu W; Zhang X
    Mol Med Rep; 2015 May; 11(5):3212-8. PubMed ID: 25572286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A theoretical model for simulating effect of parathyroid hormone on bone metabolism at cellular level.
    Wang Y; Qin QH; Kalyanasundaram S
    Mol Cell Biomech; 2009 Jun; 6(2):101-12. PubMed ID: 19496258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of osteoprotegerin/receptor activator of nuclear factor kappa B/receptor activator of nuclear factor kappa B ligand axis in nonalcoholic fatty liver disease.
    Pacifico L; Andreoli GM; D'Avanzo M; De Mitri D; Pierimarchi P
    World J Gastroenterol; 2018 May; 24(19):2073-2082. PubMed ID: 29785076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.